Pharma/Biotech Update: Eloctate Meets Objectives in Hemophilia A Study
April 10, 2014; Posted by: WeBleed staff
Biogen Idec and Sobi announce successful study for severe hemophilia A in children under 12 years old.
A recent article written by Michael Calia at NASDAQ shows promise for Biogen Idec’s up and coming hemophilia A (factor VIII deficiency) factor medication. Calia goes into detail about “Eloctate” and a current study being done. The drug is currently in Phase 3 trials and is being overseen and reviewed by numerous countries before getting approval.
Read more about Biogen Idec’s FDA progress here
Both Biogen Idec and Sobi, a leading integrated biopharmaceutical company based out of Sweden dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families, said the study’s success will back regulatory applications in Europe. With the completion of this study, the approval date for “Eloctate” may get a push in the right direction. 2014-2015 continues to be a ripe year for some major pharmaceutical approvals, especially in the bleeding disorders community.
Photo Credit – Biogen Idec
